Index 223 Negative predictive value (NPV), 200, 201f Negative reinforcement, 37–38 Neologisms, 88 Neonates. See also Infants reflexes, 5–6 Neuroanatomy, 75–76 Neuroleptic malignant syndrome (NMS), 91 Neuropeptides, 81–82 Neurotensin, 82 Neurotransmitters, 77–78 alterations in psychiatric conditions, 78t release steps, 77 NMDA (N-methyl-D-aspartate), 114 NMS (neuroleptic malignant syndrome), 91 Nominal data, 214 Nonassociative learning, 35, 39–41 Nonmaleficence, 181 Nonrapid eye movement (NREM), 43–45 Norepinephrine aggression and, 63 as biogenic amine, 79 MHPG, 79 sexual response and, 55 synthesis, 79 Normal distribution, 209 NOS (Eating Disorder Not Otherwise Specified), 156 NPV (negative predictive value), 200, 201f NREM (nonrapid eye movement), 43–45 Null hypothesis (H 0 ), 212 Nursing homes, 194 O Observational learning, 39 Observational study, 202 Obsessive-compulsive disorder (OCD), 28, 103, 105–106, 132 Obsessive-compulsive personality disorder (OCPD), 28, 103, 106, 132 Obstructive sleep apnea (OSA), 46–47 OCD. See Obsessive-compulsive disorder OCPD. See Obsessive-compulsive personality disorder Odds ratio (OR), 206 Open-ended questions, 179 Operant conditioning, 35, 37–39 Opiates, 146 Opioid receptors location, 145 mechanisms of action, 145 types, 145 Opioids agonists, 145–146 antagonists, 145 endogenous, 82 mechanisms of action, 145 opiates v., 146 Oppositional defiant disorder, 161 OR (odds ratio), 206 Oral phase, 4 Ordinal data, 214 Orgasmic disorder, 52 OSA (obstructive sleep apnea), 46–47 Osteoporosis, 17 Overdose, narcotic, 147 Oxycodone, 146 Oxytocin, 82 P p (probability) value, 213 Palliative care, 186, 194 Palmar grasp, 6 Panic disorder, 103–105 Papaverine, 53 Parachute reflex, 6 Paranoid personality disorder, 29, 126–127 Paranoid schizophrenia, 89 Paraphilias, 54 Parasomnias, 45 Parietal lobe lesion, 76 Parkinson’s disease, 78–79 Parotiditis, 155 Paroxetine, 95t, 167–168 Passive suicidal ideation, 67 Patient adherence, 179 Patient autonomy, 181 Patient confidentiality, 178, 187–188 Patient referrals. See Referrals, patient Pavlov’s classical conditioning, 36, 36f Paxil. See Paroxetine Pedigree study, 69 Pedophilia, 54 Pentazocine, 146 Peripheral nervous system (PNS), 75–76 Personality disorders, 66, 125–133 classification, 125–126 cluster A, 126–127 cluster B, 127–128 cluster C, 130–131 definition, 125 diagnostic criteria, 125 psychosis and, 86 Pervasive development disorders, 159–161 Asperger disorder, 159–160 autistic disorder, 159–160 childhood disintegrative disorder, 159, 161 Rett disorder, 159–160 Phallic phase, 4 Phencyclidine, 144. See also Substance abuse Phentolamine, 53 Phobias, 37 Physician impairment, 182 Piaget, Jean, 3–5 PNS (peripheral nervous system), 75–76
224 Index “Pooled-risk,” 192 Positive predictive value (PPV), 200, 201f Positive reinforcement, 37–38 Postpartum “blues,” 15–16 Postpartum major depression, 16, 94 Postpartum psychosis, 16 Posttraumatic stress disorder (PTSD), 62, 103, 107–108 adjustment disorder v., 108 ASD v., 108 suicide and, 66 Power, 212–213 Power of attorney, 184 PPOs (preferred provider organizations), 193 PPV (positive predictive value), 200, 201f Prazosin, 108 Precision, 204 Preferred provider organizations (PPOs), 193 Pregnancy and childbirth benzodiazepines during, 165 bipolar disorder and, pharmacologic treatment, 173 postpartum period, 15–16 “blues,” 15–16 major depression, 16 psychosis, 16 Premature birth, 5 Premature ejaculation, 52 Prevalence, 199 Priapism, 168 Primary process thinking, 26 Principle of double-effect, 181 Probability (p) value, 213 Progesterone, 51 Projection, as defense mechanism, 27, 29 Prospective study, 201 Prozac. See Fluoxetine Psychiatric disorders, 69–71. See also Major depressive disorder; Psychosis; Schizophrenia Psychoanalytic theory, 25–33 defense mechanisms, 26–30, 31–32t psychotherapy, 26–27 structural theory of the mind, 25 topographic theory of the mind, 25 Psychosis, 85–86 clinical hallmarks, 85 hallucinations, 85–86 from medical conditions, 86 narcolepsy and, 86 personality disorders and, 86 from pharmacological agents, 171 postpartum, 16 Psychotherapy, 26–27 for major depressive disorder, 98–99 psychodynamic, 26–27 for specific phobia, 109 Psychotic disorders, 85–92 PTSD. See Posttraumatic stress disorder Punishment, 37–38 Purging, 155 Q Quaternary amines, 78 R r (correlation coefficient), 211 Rape, 61–62 Rapid eye movement (REM), 20, 43–45 Rapport, 177 Ratio data, 214 Rationalization, as defense mechanism, 27–28 Reaction formation, as defense mechanism, 27–28 Referrals, patient, 177 Refusal of treatment by patients, 186 by physicians, 187 Regression, as defense mechanism, 27, 29 Reinforcement, in operant conditioning, 37–39 Relapse, 142, 150 Relative risk (RR), 205–206, 205f Reliability, 204 REM (rapid eye movement), 20, 43–45 Remeron. See Mirtazapine Repression, as defense mechanism, 27, 29 Research study designs, 201–203 Reserpine, 94 Reticular system lesion, 76 Retrospective study, 202 Rett disorder, 159–160 Risperidone, 172 Ritalin, 46 Rivastigmine, 114 Romazicon. See Flumazenil Rooting reflex, 6 RR (relative risk), 205–206, 205f S Schizoaffective disorder, 86, 91 Schizoid personality disorder, 126, 130–131 Schizophrenia, 69–70, 87–91 abnormal thought formation, 88 antipsychotics for, 90 catalepsy, 90 catatonic, 89 characteristic symptoms, 87–88 disorganized speech, 87
- Page 2 and 3:
DEJA REVIEW TM Behavioral Science
- Page 4 and 5:
DEJA REVIEW TM Behavioral Science S
- Page 6 and 7:
To my family
- Page 8 and 9:
Contents Faculty Reviewers/Student
- Page 10 and 11:
Contents ix Chapter 13 MOOD DISORDE
- Page 12 and 13:
Faculty Reviewers Debra L Klamen, M
- Page 14 and 15:
Preface Behavioral science is an ex
- Page 16 and 17:
SECTION I Human Development and Psy
- Page 18 and 19:
CHAPTER 1 Early Stages of Life: Inf
- Page 20 and 21:
Early Stages of Life: Infancy to Ch
- Page 22 and 23:
Early Stages of Life: Infancy to Ch
- Page 24 and 25:
Early Stages of Life: Infancy to Ch
- Page 26 and 27:
Early Stages of Life: Infancy to Ch
- Page 28 and 29:
Early Stages of Life: Infancy to Ch
- Page 30 and 31:
CHAPTER 2 Middle Stages of Life: Ad
- Page 32 and 33:
Middle Stages of Life: Adolescence
- Page 34 and 35:
CHAPTER 3 Late Stages of Life: Agin
- Page 36 and 37:
Late Stages of Life: Aging, Death,
- Page 38 and 39:
Late Stages of Life: Aging, Death,
- Page 40 and 41:
CHAPTER 4 Psychoanalytic Theory Wha
- Page 42 and 43:
Psychoanalytic Theory 27 What are t
- Page 44 and 45:
Psychoanalytic Theory 29 Which defe
- Page 46:
Table 4.1 Defense Mechanism Descrip
- Page 50 and 51:
Psychoanalytic Theory 33 CLINICAL V
- Page 52 and 53:
CHAPTER 5 Learning Theory What is b
- Page 54 and 55:
Learning Theory 37 What is the term
- Page 56 and 57:
Learning Theory 39 What are the dif
- Page 58 and 59:
Learning Theory 41 What is sensitiz
- Page 60 and 61:
CHAPTER 6 Sleep Science and Disorde
- Page 62 and 63:
Sleep Science and Disorders 45 Whic
- Page 64 and 65:
Sleep Science and Disorders 47 In a
- Page 66 and 67:
CHAPTER 7 Sexuality SEXUAL DEVELOPM
- Page 68 and 69:
Sexuality 51 What is the sexual ori
- Page 70 and 71:
Sexuality 53 Which disorder is char
- Page 72 and 73:
Sexuality 55 Which postmyocardial i
- Page 74 and 75:
CHAPTER 8 Abuse and Aggression CHIL
- Page 76 and 77:
Abuse and Aggression 59 Which gende
- Page 78 and 79:
Abuse and Aggression 61 SEXUAL VIOL
- Page 80 and 81:
Abuse and Aggression 63 Why are man
- Page 82 and 83:
CHAPTER 9 Suicide SUICIDE What is i
- Page 84 and 85:
Suicide 67 At what stage, in treate
- Page 86 and 87:
CHAPTER 10 Genetic Basis of Behavio
- Page 88 and 89:
Genetic Basis of Behavior 71 Do per
- Page 90 and 91:
Genetic Basis of Behavior 73 A 19-y
- Page 92 and 93:
CHAPTER 11 Neurochemistry in Behavi
- Page 94 and 95:
Neurochemistry in Behavioral Scienc
- Page 96 and 97:
Neurochemistry in Behavioral Scienc
- Page 98 and 99:
Neurochemistry in Behavioral Scienc
- Page 100 and 101:
SECTION II Psychiatric Disorders an
- Page 102 and 103:
CHAPTER 12 Psychotic Disorders INTR
- Page 104 and 105:
Psychotic Disorders 87 Schizophreni
- Page 106 and 107:
Psychotic Disorders 89 Does gender
- Page 108 and 109:
Psychotic Disorders 91 What are som
- Page 110 and 111:
CHAPTER 13 Mood Disorders What are
- Page 112 and 113:
Mood Disorders 95 Table 13.1 SSRIs
- Page 114 and 115:
Mood Disorders 97 Table 13.2 Other
- Page 116 and 117:
Mood Disorders 99 What is electroco
- Page 118 and 119:
Mood Disorders 101 How do you diagn
- Page 120 and 121:
CHAPTER 14 Anxiety Disorders What a
- Page 122 and 123:
Anxiety Disorders 105 What differen
- Page 124 and 125:
Anxiety Disorders 107 What differen
- Page 126 and 127:
Anxiety Disorders 109 What characte
- Page 128 and 129:
CHAPTER 15 Cognitive Disorders Name
- Page 130 and 131:
Cognitive Disorders 113 How does de
- Page 132 and 133:
Cognitive Disorders 115 AMNESTIC SY
- Page 134 and 135:
CHAPTER 16 Somatoform Disorders Wha
- Page 136 and 137:
Somatoform Disorders 119 What is th
- Page 138 and 139:
Somatoform Disorders 121 BODY DYSMO
- Page 140 and 141:
Somatoform Disorders 123 What is th
- Page 142 and 143:
CHAPTER 17 Personality Disorders Wh
- Page 144 and 145:
Personality Disorders 127 What is t
- Page 146 and 147:
Personality Disorders 129 What are
- Page 148 and 149:
Personality Disorders 131 How can a
- Page 150 and 151:
Personality Disorders 133 CLINICAL
- Page 152 and 153:
CHAPTER 18 Dissociative Disorders W
- Page 154 and 155:
Dissociative Disorders 137 A 42-yea
- Page 156 and 157:
CHAPTER 19 Substance Abuse Disorder
- Page 158 and 159:
Substance Abuse Disorders 141 How c
- Page 160 and 161:
Substance Abuse Disorders 143 What
- Page 162 and 163:
Substance Abuse Disorders 145 What
- Page 164 and 165:
Substance Abuse Disorders 147 What
- Page 166 and 167:
Substance Abuse Disorders 149 Serum
- Page 168 and 169:
Substance Abuse Disorders 151 CLINI
- Page 170 and 171:
CHAPTER 20 Eating Disorders What ar
- Page 172 and 173:
Eating Disorders 155 What are commo
- Page 174 and 175:
Eating Disorders 157 A 12-year-old
- Page 176 and 177:
CHAPTER 21 Child Psychiatry PERVASI
- Page 178 and 179:
Child Psychiatry 161 What happens t
- Page 180 and 181:
Child Psychiatry 163 In which age g
- Page 182 and 183:
CHAPTER 22 Psychopharmacology What
- Page 184 and 185:
Psychopharmacology 167 Which benzod
- Page 186 and 187:
Psychopharmacology 169 What are the
- Page 188 and 189:
Psychopharmacology 171 What is the
- Page 190 and 191: Psychopharmacology 173 Which pharma
- Page 192 and 193: SECTION III Ethics, Health Care, an
- Page 194 and 195: CHAPTER 23 Clinical Practice and Di
- Page 196 and 197: Clinical Practice and Difficult Sit
- Page 198 and 199: CHAPTER 24 Medical Ethics and Legal
- Page 200 and 201: Medical Ethics and Legal Issues 183
- Page 202 and 203: Medical Ethics and Legal Issues 185
- Page 204 and 205: Medical Ethics and Legal Issues 187
- Page 206 and 207: Medical Ethics and Legal Issues 189
- Page 208 and 209: CHAPTER 25 Health Care in the Unite
- Page 210 and 211: Health Care in the United States 19
- Page 212 and 213: Health Care in the United States 19
- Page 214 and 215: Health Care in the United States 19
- Page 216 and 217: CHAPTER 26 Epidemiology and Researc
- Page 218 and 219: Epidemiology and Research Design 20
- Page 220 and 221: Epidemiology and Research Design 20
- Page 222 and 223: Epidemiology and Research Design 20
- Page 224 and 225: Epidemiology and Research Design 20
- Page 226 and 227: CHAPTER 27 Biostatistics STATISTICA
- Page 228 and 229: Biostatistics 211 What is a depende
- Page 230 and 231: Biostatistics 213 If the sample siz
- Page 232 and 233: Biostatistics 215 Which type of t-t
- Page 234 and 235: Index A Abnormal thought formation,
- Page 236 and 237: Index 219 Celexa. See Citalopram Ce
- Page 238 and 239: Index 221 F Factitious disorder, 11
- Page 242 and 243: Index 225 Schizophrenia (Cont.): do